CDOP regimen
|
WikiDoc Resources for CDOP regimen |
|
Articles |
|---|
|
Most recent articles on CDOP regimen Most cited articles on CDOP regimen |
|
Media |
|
Powerpoint slides on CDOP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CDOP regimen at Clinical Trials.gov Clinical Trials on CDOP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CDOP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CDOP regimen Discussion groups on CDOP regimen Patient Handouts on CDOP regimen Directions to Hospitals Treating CDOP regimen Risk calculators and risk factors for CDOP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CDOP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
CDOP regimen refers to an immunochemotherapy regimen consisting of Cyclophosphamide, Doxorubicin (Doxil), Vincristine (Oncovin), Prednisone used to treat Diffuse large B-cell lymphoma
Regimen
CCyclophosphamide
DDoxorubicin Liposomal (Doxil)
OVincristine (Oncovin)
PPrednisone
Indications
References
- ↑ Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP; et al. (2002). "Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study". Haematologica. 87 (8): 822–7. PMID 12161358.